Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells
Background: The clinical impact of the monoclonal antibody cetuximab targeting the EGFR in colorectal cancer (CRC) is widely recognized. Nevertheless, the onset of cetuximab resistance is a serious issue that limits the effectiveness of this drug in targeted therapies. Unraveling the molecular playe...
Main Authors: | Rosita Russo, Nunzia Matrone, Valentina Belli, Davide Ciardiello, Mariangela Valletta, Sabrina Esposito, Paolo Vincenzo Pedone, Fortunato Ciardiello, Teresa Troiani, Angela Chambery |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/10/1430 |
Similar Items
-
Cetuximab in first line treatment of metastatic colorectal cancer
by: Carlo Barone, et al.
Published: (2012-07-01) -
EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
by: Andrea Uhlyarik, et al.
Published: (2020-03-01) -
Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy
by: Wiebke Sihver, et al.
Published: (2014-03-01) -
Effects of Monoclonal Antibody Cetuximab on Proliferation of Non-small Cell Lung Cancer Cell lines
by: Zhen CHEN, et al.
Published: (2010-08-01) -
A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer
by: Markus Hecht, et al.
Published: (2021-07-01)